Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

Pemetrexed (used as a platinum doublet or as a maintenance regimen) is an established therapy for patients with advanced non-squamous non-small-cell lung cancer (NSCLC). In addition, certain gene rearrangements (e.g., ALK, ROS1, RET) appear to especially benefit from the use of pemetrexed. Inferior outcomes with pemetrexed compared to other chemotherapies in patients with NSCLC demonstrating squamous histology removed these patients from the labeled indication for the drug. While most squamous cases do not harbor driver oncogenes, rare exceptions exist. Whether the poor outcomes with pemetrexed extend to NSCLC with squamous component harboring driver oncogenes remains unexplored. In this case series, we describe two patients with adenosquamous histology harboring an ROS1 and ALK gene arrangement, respectively, who derived significant benefit from pemetrexed-based therapy. These cases suggest that the value of pemetrexed may need to be re-explored in adenosquamous NSCLC harboring such alterations.

Download Full-text

A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non–Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements

Clinical Lung Cancer ◽

10.1016/j.cllc.2013.04.008 ◽

2013 ◽

Vol 14 (5) ◽

pp. 592-595 ◽

Cited By ~ 26

Author(s):

Jonathan W. Riess ◽

Sukhmani K. Padda ◽

Charles D. Bangs ◽

Millie Das ◽

Joel W. Neal ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Case Series ◽

Progression Free Survival ◽

Small Cell ◽

Gene Rearrangements ◽

Small Cell Lung ◽

Free Survival ◽

Lung Cancer Patients

Download Full-text

PCN183 A Cost-Effectiveness Analysis of Nivolumab plus Ipilimumab plus Two Cycles of Platinum Doublet-Chemotherapy Versus Platinum Doublet Chemotherapy in the First-Line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer in Canada

Value in Health ◽

10.1016/j.jval.2021.04.274 ◽

2021 ◽

Vol 24 ◽

pp. S53

Author(s):

K.C. Young ◽

H. Sandhu ◽

A. Lee ◽

K. Lakhdari ◽

J. Maervoet ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

Doublet Chemotherapy ◽

First Line Treatment ◽

Platinum Doublet

Download Full-text

Intracranial complications from immune checkpoint therapy in a patient with non-small cell lung cancer and multiple sclerosis: Case report

JTO Clinical and Research Reports ◽

10.1016/j.jtocrr.2021.100183 ◽

2021 ◽

pp. 100183

Author(s):

Benjamin Y. Lu ◽

Cigdem Isitan ◽

Amit Mahajan ◽

Veronica Chiang ◽

Anita Huttner ◽

...

Keyword(s):

Multiple Sclerosis ◽

Lung Cancer ◽

Case Report ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Immune Checkpoint ◽

Small Cell ◽

Small Cell Lung ◽

Multiple Sclerosis Case ◽

Intracranial Complications

Download Full-text

Pathological complete response to neoadjuvant ceritinib of a crizotinib‐resistant, stage IIIB non‐small cell lung cancer with ALK rearrangement: A case report

Thoracic Cancer ◽

10.1111/1759-7714.14045 ◽

2021 ◽

Author(s):

Zhongxing Bing ◽

Ziqi Jia ◽

Yadong Wang ◽

Jianchao Xue ◽

Lei Cao ◽

...

Keyword(s):

Lung Cancer ◽

Case Report ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Pathological Complete Response ◽

Complete Response ◽

Small Cell ◽

Stage Iiib ◽

Small Cell Lung ◽

Alk Rearrangement

Download Full-text

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)

Therapeutic Advances in Medical Oncology ◽

10.1177/1758835920987647 ◽

2021 ◽

Vol 13 ◽

pp. 175883592098764

Author(s):

Ryota Shibaki ◽

Hiroaki Akamatsu ◽

Terufumi Kato ◽

Kazumi Nishino ◽

Morihito Okada ◽

...

Keyword(s):

Lung Cancer ◽

Adjuvant Therapy ◽

Egfr Mutation ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

Resected Nsclc ◽

Egfr Mutated ◽

Doublet Chemotherapy ◽

Platinum Doublet

Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is a standard treatment in EGFR-mutated advanced non-small-cell lung cancer (NSCLC); however, previous data have suggested that EGFR-TKI has limited potential as adjuvant therapy. On the contrary, based on subset analysis with the immune checkpoint inhibitor (ICI) plus platinum-doublet chemotherapy in advanced NSCLC with EGFR mutation, we hypothesized that this combination was worth testing as adjuvant therapy in patients with EGFR-mutated NSCLC. Methods: Herein, we introduce our phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected NSCLC with EGFR mutation. Accrued patients will be pathological stage II–IIIA with completely resected NSCLC and whose tumors have EGFR mutation. Treatment comprises four cycles of cisplatin plus vinorelbine combined with atezolizumab followed by maintenance with atezolizumab. The primary endpoint is the disease-free survival (DFS) rate at 2 years. Secondary endpoints are DFS, overall survival, and safety. In total, 18 patients will be enrolled in this study. Discussion: Ongoing phase III trials of adjuvant ICI allow the inclusion of patients with EGFR mutation, but our current trial will provide the earliest clinical data on the efficacy of platinum-doublet chemotherapy with atezolizumab.

Download Full-text